UnitedHealth: The Turnaround Everyone Wants to Believe, Priced by a Market That Isn't Sure Yet

Here's the UnitedHealth setup in one sentence: a company that watched its stock get taken to the woodshed in 2025 has spent 2026 trying to convince Wall Street it learned its lesson, and Wall Street's response has been to raise its price targets while simultaneously selling the stock. That's not a typo. That's the whole story.

Let's rewind for a second. UNH got demolished after an April 2025 earnings miss — the kind of quarter that makes a mega-cap health insurer look like a meme stock, crashing from north of $575 to around $234. Then came 2026's recovery act: the stock ripped from roughly $275 in April to $461.62 in July, a face-melting rally that would make any turnaround investor feel vindicated. Except it didn't stop there — it kept going, right into a pullback, and as of today UNH sits at $392.50, about 15% off that July high and stuck in the middle of a multi-month consolidation.

The good news is real. Q2 2026 earnings, reported in mid-July, showed adjusted EPS of $6.38 versus $4.08 a year ago, and — this is the number that actually matters — the medical care ratio improved to 86.7% from 89.4%. MCR blowouts are exactly what torched this stock in 2025, so seeing that ratio head the right direction is the single most important data point in this entire thesis. Management raised full-year guidance. Analysts responded by yanking their mean price target up 15%, from $412 to $475, in about seven weeks.

And yet the stock fell 7% over that same window, from $416 to $389. Read that twice. When price targets go up and the stock goes down at the same time, that's not noise — that's the market telling you it doesn't fully believe the story yet. Add in a couple of unflattering wrinkles: sequential EPS actually declined, from $7.23 in Q1 2026 to $6.38 in Q2, and Berkshire Hathaway disclosed it exited its UNH stake entirely as part of Greg Abel's portfolio reshuffle, which knocked the stock down more than 2% on the news. Erste Group cut it to Hold. Humana's warning about individual Medicare Advantage membership declines is a sector-wide flag, not just a UNH problem, but it's still a headwind blowing UNH's way.

Then there's the noise that isn't really about fundamentals at all — the stock popped on the Luigi Mangione guilty plea, which is a genuinely strange sentence to type but tells you everything about how much reputational and political overhang trades alongside this name now. CMS proposing an effective Medicare Advantage rate cut for FY2027 (a net 0.09% increase that doesn't even cover medical inflation) is the regulatory sword hanging over the whole managed-care sector, UNH included.

Where does that leave valuation? Actually reasonable, which is the most underrated part of this story. Forward P/E of 17.5, PEG around 1.03, free cash flow machine still churning — TTM FCF of $24.3 billion, comfortably covering a dividend that's yielding about 2.4% at a 66% payout ratio. The balance sheet is stretched (debt-to-equity around 0.74, current ratio under 1), which is normal for an insurer but leaves less room for error than a decade of pre-2025 UNH investors got used to. Trailing profit margins (3.14%) and ROE (14.6%) are still shadows of the 6%+/25%+ this business used to print — the whole bull case rests on believing MCR normalization is real and durable, not a one-quarter fluke.

Technically, this is a stock with no conviction in either direction. RSI sits at 42, price is below both the 20-day and 50-day averages but still up double digits versus the 200-day — a classic "give me more evidence" chart. Support sits at $384 and then $360; resistance is $410, then $432, then that July high at $461.

My take: this is a legitimate accumulate, not a chase. The MCR data is the real signal and it's pointing the right way, the cash flow supports the dividend and the buyback (at least $5 billion committed for the year, $4 billion already done by mid-July), and the valuation isn't demanding a miracle. But size it like you mean it — small, patient, willing to add on weakness toward $384 rather than the top of the range. The stock needs one more clean quarter without a Berkshire-sized surprise attached to it before the "turnaround" stops needing air quotes.